Scipher to use proprietary patient molecular data analyzed by its Spectra^TM platform to identify novel drug targets. TARA Biosystems to progress selected targets in its Biowire^TM II drug discovery platform for cardiac laminopathies. Partnership set to reduce target discovery and validation from years down …

NEW YORK, NY - (EurekAlert) - VantAI and TARA Biosystems today announced the launch of a biology-driven, AI-enabled collaboration for accelerated cardiac drug development. The partnership will leverage TARA’s state-of-the-art in vitro human …

NEW YORK, NY - (BUSINESS WIRE) - TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 …

NEW YORK, NY - (Newswire.com) - TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a

NEW YORK, NY (Newswire.com) -​​ TARA Biosystems, Inc. launched Cardiotype.Ca™, its in vitro system for assessing cardiac calcium signaling. The new assay can be used independently or in combination with TARA’s <…

NEW YORK, N.Y. (Newswire.com)— Researchers from TARA Biosystems, Inc. and GlaxoSmithKline (GSK) today published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The …

NEW YORK, N.Y. (Newswire.com)— TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the execution of an exclusive worldwide license agreement with Columbia …

New York, NY, (Newswire.com) - TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced that the United States Patent and Trademark Office (USPTO) has …

NEW YORK, (Newswire.com) TARA Biosystems, Inc., a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the first peer-reviewed publication of its Biowire™ II platform by a team of …

New York – TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and risk assessment applications and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases, announced today the launch of a collaboration to discover and develop novel therapies for …